Skip to main content
Top
Published in: Drugs & Aging 10/2014

01-10-2014 | Short Communication

Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects

Authors: David J. Greenblatt, Jerold S. Harmatz, Nikhilesh N. Singh, Frank Steinberg, Thomas Roth, Stephen C. Harris, Ram P. Kapil

Published in: Drugs & Aging | Issue 10/2014

Login to get access

Abstract

Background

Pharmacokinetic parameters of sedative–hypnotic medications can be influenced by age and gender.

Objective

This study analyzed pharmacokinetic parameters of zolpidem, formulated as a sublingual zolpidem tartrate tablet (ZST; Intermezzo®), in healthy elderly males and females (mean age 72 years) and in non-elderly males and females (34 years).

Methods

This was a randomized, single-dose, open-label, two-way crossover study evaluating pharmacokinetic parameters of 1.75 and 3.5 mg dosages of ZST in elderly subjects (n = 22), and 3.5 mg dosages of ZST in non-elderly subjects (n = 24). Main outcome measures were pharmacokinetic parameters, including area under the plasma concentration–time curve (AUC), maximum observed concentration (C max), time to reach C max (T max), elimination half-life (T ½), and apparent oral clearance (CL/F).

Results

Dose proportionality in zolpidem exposure was maintained between 1.75 and 3.5 mg doses for both elderly females and males. With administration of the 3.5 mg dose of ZST to elderly and non-elderly subjects, significantly higher systemic exposure was seen in elderly females (C max +44.6 %, P < 0.01; AUC +40.4 %) compared with non-elderly females. However, systemic exposure was only modestly higher in elderly males compared with non-elderly males. Greater exposure was seen in elderly females compared to males (C max +46.8 %, P < 0.01; AUC +31.4 %). In this study, exposure between non-elderly females and males was equivalent. Changes in T ½ and T max values were not observed, with no significant age effect on oral clearance. There were no apparent differences in tolerability among age and gender groups.

Conclusion

Elderly individuals were found to have higher C max and AUC values compared with non-elderly subjects. C max and AUC were greater in elderly women compared with elderly men.
Literature
2.
go back to reference Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57:761–89.PubMedCrossRefPubMedCentral Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57:761–89.PubMedCrossRefPubMedCentral
5.
go back to reference Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.PubMedCrossRef Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.PubMedCrossRef
7.
go back to reference Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations. Clin Pharmacokinet. 1991;21:165–77, 262–73. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations. Clin Pharmacokinet. 1991;21:165–77, 262–73.
8.
go back to reference Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Therapeutics. 2004;76:467–79.CrossRef Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Therapeutics. 2004;76:467–79.CrossRef
9.
go back to reference Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clinical Pharmacokinet. 2005;44:33–60.CrossRef Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clinical Pharmacokinet. 2005;44:33–60.CrossRef
10.
go back to reference Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.PubMedCrossRefPubMedCentral Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.PubMedCrossRefPubMedCentral
11.
12.
go back to reference Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol. 2011;31:1–3.PubMedCrossRef Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol. 2011;31:1–3.PubMedCrossRef
13.
go back to reference Bianchetti G, Dubruc C, Thiercelin JF, Bercoff E, Bouchet JL, Emeriau JP, Galperine I, Lambert D, Vandel B, Thebalt JJ. Clinical pharmacokinetics of zolpidem in various psychological and pathological conditions. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press; 1988. p. 155–63. Bianchetti G, Dubruc C, Thiercelin JF, Bercoff E, Bouchet JL, Emeriau JP, Galperine I, Lambert D, Vandel B, Thebalt JJ. Clinical pharmacokinetics of zolpidem in various psychological and pathological conditions. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press; 1988. p. 155–63.
14.
go back to reference Olubodun JO, Ochs HR, von Moltke LL, Roubenoff R, Hesse LM, Harmatz JS, Shader RI, Greenblatt DJ. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003;56:297–304.PubMedCrossRefPubMedCentral Olubodun JO, Ochs HR, von Moltke LL, Roubenoff R, Hesse LM, Harmatz JS, Shader RI, Greenblatt DJ. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003;56:297–304.PubMedCrossRefPubMedCentral
15.
go back to reference Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Durol ALB, Harrel-Joseph LM, Shader RI. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Therapeutics. 2000;293:435–43. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Durol ALB, Harrel-Joseph LM, Shader RI. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Therapeutics. 2000;293:435–43.
16.
go back to reference Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP. Pharmacokinetic profile of buffered sublingual zolpidem compared with oral immediate release zolpidem. Clin Therapeutics. 2013;35:604–11.CrossRef Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP. Pharmacokinetic profile of buffered sublingual zolpidem compared with oral immediate release zolpidem. Clin Therapeutics. 2013;35:604–11.CrossRef
17.
go back to reference Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol. 2014;54:282–90.PubMedCrossRef Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol. 2014;54:282–90.PubMedCrossRef
18.
go back to reference Roth T, Mayleben D, Corser BC, Singh NN. Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol. 2008;23:13–20.PubMedCrossRefPubMedCentral Roth T, Mayleben D, Corser BC, Singh NN. Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol. 2008;23:13–20.PubMedCrossRefPubMedCentral
19.
go back to reference Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep. 2008;31:1277–84.PubMedPubMedCentral Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep. 2008;31:1277–84.PubMedPubMedCentral
20.
go back to reference Lankford A. Sublingual zolpidem tartrate lozenge for the treatment of insomnia. Expert Rev Clin Pharmacol. 2009;2:333–7.PubMedCrossRef Lankford A. Sublingual zolpidem tartrate lozenge for the treatment of insomnia. Expert Rev Clin Pharmacol. 2009;2:333–7.PubMedCrossRef
21.
go back to reference Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013;36:189–96.PubMedPubMedCentral Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013;36:189–96.PubMedPubMedCentral
22.
go back to reference Ownby RL. New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets. Nat Sci Sleep. 2010;2:63–9.PubMedCrossRefPubMedCentral Ownby RL. New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets. Nat Sci Sleep. 2010;2:63–9.PubMedCrossRefPubMedCentral
23.
go back to reference Ohayon MM. Nocturnal awakenings and comorbid disorders in the American general population. J Psychiatr Res. 2009;43:48–54.CrossRef Ohayon MM. Nocturnal awakenings and comorbid disorders in the American general population. J Psychiatr Res. 2009;43:48–54.CrossRef
24.
go back to reference Ohayon MM. Nocturnal awakenings and difficulty resuming sleep: their burden in the European general population. J Psychosom Res. 2010;69:565–71.PubMedCrossRef Ohayon MM. Nocturnal awakenings and difficulty resuming sleep: their burden in the European general population. J Psychosom Res. 2010;69:565–71.PubMedCrossRef
25.
go back to reference Roth T, Berglund P, Shahly V, Shillington AC, Stephenson JJ, Kessler RC. Middle-of-the-night hypnotic use in a large national health plan. J Clin Sleep Med. 2013;9:661–8.PubMedPubMedCentral Roth T, Berglund P, Shahly V, Shillington AC, Stephenson JJ, Kessler RC. Middle-of-the-night hypnotic use in a large national health plan. J Clin Sleep Med. 2013;9:661–8.PubMedPubMedCentral
26.
go back to reference von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol. 1999;48:89–97.CrossRef von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol. 1999;48:89–97.CrossRef
27.
go back to reference Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol. 2008;48:1350–5.PubMedCrossRef Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol. 2008;48:1350–5.PubMedCrossRef
28.
go back to reference Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traffic Inj Prev. 2012;13:286–92.PubMedCrossRef Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traffic Inj Prev. 2012;13:286–92.PubMedCrossRef
29.
go back to reference Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment—identifying persons at risk. N Engl J Med. 2013;369:689–91.PubMedCrossRef Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment—identifying persons at risk. N Engl J Med. 2013;369:689–91.PubMedCrossRef
30.
go back to reference Greenblatt DJ. Sleep-promoting medications: weighing the hazards of use versus non-use. Clin Pharmacol Drug Dev. 2014;3:167–9.CrossRef Greenblatt DJ. Sleep-promoting medications: weighing the hazards of use versus non-use. Clin Pharmacol Drug Dev. 2014;3:167–9.CrossRef
Metadata
Title
Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects
Authors
David J. Greenblatt
Jerold S. Harmatz
Nikhilesh N. Singh
Frank Steinberg
Thomas Roth
Stephen C. Harris
Ram P. Kapil
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 10/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0211-3

Other articles of this Issue 10/2014

Drugs & Aging 10/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.